Recent

% | $
Quotes you view appear here for quick access.

Insmed Incorporated Message Board

  • fasano98 fasano98 Dec 5, 2013 12:54 PM Flag

    anyone know the answer to this Iplex question

    When Increlex goes off patent in Sept 2017, do you know (based upon the legal settlement with Tercica / Ipsen) if Insmed will be able to market Iplex as a generic. Do you know?

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • The legal settlement expires when the last remaining infringed patent expires. As far as I am aware that patent is the Genentech '414 patent licensed to Ipsen, due to expire some time in 2018.

      I can't personally see Insmed investing any money in iPlex any time soon. There must be loads of other approved therapies out there for pulmonary conditions which would be far more effective if delivered via inhaled liposomes. But once Ipsen and Genetech no longer have a claim on iPlex I'm sure Insmed will be only too happy to out-license their IP to whoever sees commercialisation potential in iPlex.

    • Iplex and Increlex are not the same drug. Not even close. The legal settlement was in regard to the
      method of production that caused both drugs to be made. INSM infringed on the methodology that
      Tercica owned the patten to, and therefor is not permitted to be produced for the indication that IPLEX
      was approved for.

    • Why would they market it as a generic? They can just market it as Iplex. It isn't a duplicate of Increlex at all and is proven to be far, far safer and more effective. This is why they were so adamant about getting Iplex off of the market.

      Sentiment: Buy

 
INSM
11.83-0.05(-0.42%)May 27 4:00 PMEDT